<DOC>
	<DOCNO>NCT00022178</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know combination chemotherapy regimen effective metastatic cancer unknown site origin . PURPOSE : Randomized phase III trial compare effectiveness two combination chemotherapy regimens treat patient metastatic cancer unknown site origin .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Metastatic Cancer Unknown Site Origin</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy regimen , term tumor response , progression-free survival , overall survival vincristine , doxorubicin , cyclophosphamide v epirubicin , cisplatin , fluorouracil patient metastatic carcinoma unknown primary . II . Compare toxicity regimens patient . III . Compare quality life symptom control patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord presence liver metastasis ( yes v ) type tumor ( adenocarcinoma v non-adenocarcinoma ) . Patients randomize one two treatment arm . Arm I : Patients receive vincristine IV , doxorubicin IV , cyclophosphamide IV day 1 . Arm II : Patients receive epirubicin IV cisplatin IV 4 hour day 1 fluorouracil IV continuously day 1-21 . Treatment arm repeat every 3 week 3-6 course absence disease progression unacceptable toxicity . Quality life assess baseline , end course 2 , 4 , 6 , 1 month completion therapy . Patients follow 1 month death . PROJECTED ACCRUAL : A total 398 patient ( 199 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic carcinoma unknown primary Adenocarcinoma nonadenocarcinoma No axillary lymph node metastasis sole site disease female patient No peritoneal carcinomatosis sole site disease female patient No squamous cell carcinoma cervical lymph node sole site disease male female patient No neuroendocrine tumor No elevate alphafetoprotein , betaHCG , PSA PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 1.8 mg/dL Renal : Creatinine le 1.5 time upper limit normal ( ULN ) Urea le 1.5 time ULN Glomerular filtration rate least 60 mL/min Cardiovascular : LVEF least 50 % echocardiogram MUGA scan No uncontrolled angina pectoris No heart failure No clinically significant uncontrolled cardiac arrhythmia No abnormal EKG Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 year study No prior malignancy except adequately treat nonmelanoma skin cancer carcinoma situ cervix No medical psychiatric condition would preclude study No serious uncontrolled medical condition PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy carcinoma unknown primary Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow except sole site measurable evaluable disease Concurrent palliative radiotherapy allow except sole site measurable evaluable disease Surgery : Not specify Other : No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2002</verification_date>
	<keyword>adenocarcinoma unknown primary</keyword>
	<keyword>squamous cell carcinoma unknown primary</keyword>
	<keyword>undifferentiated carcinoma unknown primary</keyword>
	<keyword>newly diagnose carcinoma unknown primary</keyword>
</DOC>